(4-(Bis(4-Fluorophenyl)Methyl)Piperazin-1-yl)(Cyclohexyl)Methanone Hydrochloride (LDK1229): A New Cannabinoid CB1 Receptor Inverse Agonist from the Class of Benzhydryl Piperazine Analogs - Publikacja - MOST Wiedzy

Wyszukiwarka

(4-(Bis(4-Fluorophenyl)Methyl)Piperazin-1-yl)(Cyclohexyl)Methanone Hydrochloride (LDK1229): A New Cannabinoid CB1 Receptor Inverse Agonist from the Class of Benzhydryl Piperazine Analogs

Abstrakt

Some inverse agonists of cannabinoid receptor type 1 (CB1) have been demonstrated to be anorectic antiobesity drug candidates. However, the first generation of CB1 inverse agonists, represented by rimonabant (SR141716A), otenabant, and taranabant, are centrally active, with a high level of psychiatric side effects. Hence, the discovery of CB1 inverse agonists with a chemical scaffold distinct from these holds promise for developing peripherally active CB1 inverse agonists with fewer side effects. We generated a new CB1 inverse agonist, (4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride (LDK1229), from the class of benzhydryl piperazine analogs. This compound binds to CB1 more selectively than cannabinoid receptor type 2, with a Ki value of 220 nM. Comparable CB1 binding was also observed by analogs 1-[bis(4-fluorophenyl)methyl]-4-cinnamylpiperazine dihydrochloride (LDK1203) and 1-[bis(4-fluorophenyl)methyl]-4-tosylpiperazine hydrochloride (LDK1222), which differed by the substitution on the piperazine ring where the piperazine of LDK1203 and LDK1222 are substituted by an alkyl group and a tosyl group, respectively. LDK1229 exhibits efficacy comparable with SR141716A in antagonizing the basal G protein coupling activity of CB1, as indicated by a reduction in guanosine 5'-O-(3-thio)triphosphate binding. Consistent with inverse agonist behavior, increased cell surface localization of CB1 upon treatment with LDK1229 was also observed. Although docking and mutational analysis showed that LDK1229 forms similar interactions with the receptor as SR141716A does, the benzhydryl piperazine scaffold is structurally distinct from the first-generation CB1 inverse agonists. It offers new opportunities for developing novel CB1 inverse agonists through the optimization of molecular properties, such as the polar surface area and hydrophilicity, to reduce the central activity observed with SR141716A.

Cytowania

  • 3

    CrossRef

  • 0

    Web of Science

  • 3

    Scopus

Autorzy (8)

  • Zdjęcie użytkownika  Mariam M. Mahmoud

    Mariam M. Mahmoud

    • Department of Molecular and Cell Biology, University of Connecticut, Storrs, Connecticut Department of Molecular and Cell Biology
  • Zdjęcie użytkownika  Hui Liu

    Hui Liu

    • Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Kingsville, Texas Department of Pharmaceutical Sciences
  • Zdjęcie użytkownika  Derek M. Shore

    Derek M. Shore

    • Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina Department of Chemistry and Biochemistry
  • Zdjęcie użytkownika  Dow P. Hurst

    Dow P. Hurst

    • Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina Department of Chemistry and Biochemistry
  • Zdjęcie użytkownika  Patricia H. Reggio

    Patricia H. Reggio

    • Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina Department of Chemistry and Biochemistry
  • Zdjęcie użytkownika  Dai Lu

    Dai Lu

    • Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Kingsville, Texas Department of Pharmaceutical Sciences
  • Zdjęcie użytkownika  Debra A. Kendall

    Debra A. Kendall

    • Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut Department of Pharmaceutical Sciences

Cytuj jako

Pełna treść

pełna treść publikacji nie jest dostępna w portalu

Słowa kluczowe

Informacje szczegółowe

Kategoria:
Publikacja w czasopiśmie
Typ:
artykuł w czasopiśmie wyróżnionym w JCR
Opublikowano w:
MOLECULAR PHARMACOLOGY nr 87, wydanie 2, strony 197 - 206,
ISSN: 0026-895X
Język:
angielski
Rok wydania:
2015
Opis bibliograficzny:
Mahmoud M., Olszewska T., Liu H., Shore D., Hurst D., Reggio P., Lu D., Kendall D.: (4-(Bis(4-Fluorophenyl)Methyl)Piperazin-1-yl)(Cyclohexyl)Methanone Hydrochloride (LDK1229): A New Cannabinoid CB1 Receptor Inverse Agonist from the Class of Benzhydryl Piperazine Analogs// MOLECULAR PHARMACOLOGY. -Vol. 87, iss. 2 (2015), s.197-206
DOI:
Cyfrowy identyfikator dokumentu elektronicznego (otwiera się w nowej karcie) 10.1124/mol.114.095471
Weryfikacja:
Politechnika Gdańska

wyświetlono 169 razy

Publikacje, które mogą cię zainteresować

Meta Tagi